2010Animal
Hyperglycemic rat model
Powdered leaf reduced fasting and post-glucose blood glucose in a dexamethasone-induced hyperglycemia rat model at experimental doses of 250 and 500 mg/kg.
HomeResearch & Evidence
Antidiabetic Research & Evidence
Proposed mechanisms, laboratory and animal findings, study summaries, ratings and timeline.
14.Proposed Antidiabetic Mechanisms
14.1 Increased cellular glucose uptake
Experimental studies reported increased glucose uptake in insulin-responsive cells.
14.2 GLUT4 translocation
The isolated insulin-like protein was associated with increased translocation of GLUT4 toward the plasma membrane, a key process in glucose uptake by skeletal muscle and adipose tissue.
14.3 Insulin signaling
Changes involving IRS-1 suggest interaction with pathways normally activated by insulin.
14.4 Pancreatic / beta-cell effects
A laboratory study using beta-like cells differentiated from human hematopoietic stem cells reported increased insulin gene expression, increased GLUT2 expression, increased glucokinase activity, and decreased glucose-6-phosphatase activity after exposure to leaf extract.
14.5 Digestive enzyme inhibition
Experimental work has investigated inhibition of alpha-amylase and alpha-glucosidase. Inhibiting these enzymes could theoretically slow carbohydrate digestion and reduce post-meal glucose excursions.
Mechanism is not clinical proof. A plausible mechanism can explain how an intervention might work. It does not establish that the intervention is effective, safe, or appropriately dosed in humans.
15.Evidence for Blood-Glucose Reduction
Laboratory evidence
Cell and biochemical experiments provide evidence of glucose uptake, insulin-related signaling, digestive-enzyme effects, and changes in genes involved in glucose metabolism. This represents meaningful mechanistic evidence but remains preclinical.
Animal evidence
Multiple animal experiments have reported glucose-lowering effects. For example, powdered leaves reduced fasting and post-glucose blood glucose in a dexamethasone-induced hyperglycemia rat model at experimental doses of 250 and 500 mg/kg.
Human evidence
Human evidence remains very limited. The literature is dominated by cell experiments, biochemical assays, animal models, phytochemical studies, computational work, and reviews rather than large, rigorous randomized controlled trials. Current evidence does not establish a standardized clinically proven human dose or support replacement of conventional diabetes therapy.
16.Evidence Summary by Proposed Benefit
| Proposed effect | Research status | Interpretation |
|---|---|---|
| Lowering blood glucose | Cell + animal evidence; very limited clinical evidence | Promising but unproven clinically |
| Improving insulin signaling | Cell and animal studies | Mechanistically plausible |
| Antioxidant activity | Numerous laboratory assays | Supported in vitro |
| Anti-inflammatory activity | Preclinical studies | Preliminary |
| Lipid-lowering activity | Mainly animal studies | Preliminary |
| Antimicrobial activity | Mostly laboratory studies | Preliminary |
| Kidney-stone inhibition | Animal studies | Preliminary |
| Hepatoprotective effects | Animal studies | Preliminary |
| Cardioprotective effects | Primarily preclinical | Preliminary |
| Analgesic activity | Experimental/preclinical | Emerging |
| Anticancer activity | Mostly laboratory/computational | Not established as cancer therapy |
17.Antioxidant Activity
Plant extracts have demonstrated activity in common laboratory antioxidant assays such as DPPH, ABTS, and FRAP. Flavonoids and phenolic compounds are thought to contribute substantially to these effects.
Interpretation. Antioxidant activity in a test tube does not automatically translate into a demonstrated clinical health benefit in humans.
18.Kidney Stone Research
Experimental work in rats with calcium oxalate urolithiasis investigated aqueous and ethanolic stem extracts and compounds such as lupeol and stigmasterol. The findings provide preliminary preclinical evidence for possible anti-urolithiatic activity. The plant has not been established as a replacement for clinical evaluation or treatment of kidney stones in humans.
Key Study SummariesSupplement
One-line summaries of the most-cited experiments behind the plant's reputation. Full citations live in Core Scientific References.
2013Cell + animal
Insulin-like protein isolated
An orally active hypoglycemic protein (ILP) was characterized; it lowered glucose in experimental cells and diabetic mice despite structural differences from human insulin.
2016Mechanistic / cell
Insulin signaling pathway
Follow-up work reported increased glucose uptake with changes involving IRS-1 and translocation of GLUT4 toward the cell membrane.
2018Phytochemical / computational
Quercetin profiling
Chromatographic analysis detected quercetin in leaf extract, and molecular docking explored interactions with insulin-related targets.
2021Cell
Beta-like cell study
Leaf extract raised insulin and GLUT2 expression, increased glucokinase activity and decreased glucose-6-phosphatase activity in human-derived beta-like cells.
2024Human safety signal
Hypoglycemia case reports
Two published human cases described hypoglycemia associated with Insulin Plant use - the clearest clinical signal to date, and a cautionary one.
2024-2026Review
Updated pharmacological reviews
Recent reviews continue to describe real pharmacological potential while stressing the absence of standardization and clinical validation.
26.Evidence Rating
27.Key Research Findings Timeline
-
2010
Powdered leaves reduced fasting and post-glucose blood glucose in a dexamethasone-induced hyperglycemia rat model.
Animal -
2013
An insulin-like protein was isolated and demonstrated glucose-lowering activity in experimental cells and diabetic mice.
Cell + animal -
2016
Further work reported increased glucose uptake and changes involving IRS-1 and GLUT4 signaling.
Mechanistic / cell -
2018
Chromatographic work reported quercetin in leaf extract and explored insulin-related molecular interactions.
Phytochemical / computational -
2021
Leaf extract altered insulin/GLUT2 expression and glucose-metabolism enzymes in human-derived beta-like cells.
Cell -
2024
Two human case reports described hypoglycemia associated with Insulin Plant use.
Human safety signal -
2024-2026
Updated reviews continued to describe pharmacological potential while emphasizing standardization and clinical validation.
Review